Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04796896

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

Sponsor: ModernaTX, Inc.

Conditions SARS-CoV-2

Interventions Placebo mRNA-1273 mRNA-1273.214

Updated 20 times since 2021 Last updated: May 22, 2025 Started: Mar 15, 2021 Primary completion: Mar 15, 2024 Completion: Mar 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on SARS-CoV-2, this trial is completed. The trial is conducted by ModernaTX, Inc. and has accumulated 20 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2025 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Jul 2025 [monthly]

Completed PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 15 earlier versions

May 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed
Nov 2023 — May 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
Mar 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2022 — Mar 2023 [monthly]

Recruiting PHASE2_PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2_PHASE3
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE2_PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2_PHASE3
Jan 2022 — May 2022 [monthly]

Recruiting PHASE2_PHASE3
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2_PHASE3
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2_PHASE3
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2_PHASE3
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2_PHASE3
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE2_PHASE3
May 2021 — Jun 2021 [monthly]

Recruiting PHASE2_PHASE3
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ModernaTX, Inc.

Data source: ModernaTX, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anaheim, United States , Atlanta, United States , Aurora, United States , Austin, United States , Baltimore, United States , Banning, United States , Baton Rouge, United States , Binghamton, United States , Birmingham, United States and 68 more locations